uniQure N.V. (QURE) – What Are Researchers Thinking About This Stock?

uniQure N.V. (NASDAQ:QURE) has received an average rating of “Moderate Buy” from the sixteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $56.83.

A number of research analysts have issued reports on QURE shares. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. Weiss Ratings raised uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 target price on shares of uniQure in a research report on Tuesday, September 29th. The Goldman Sachs Group reduced their target price on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. Finally, UBS Group assumed coverage on uniQure in a research report on Thursday, October 15th. They set a “buy” rating and a $48.00 price target for the company.

uniQure Stock Performance

Shares of uniQure stock traded down $0.82 during midday trading on Friday, hitting $23.81. The company had a trading volume of 1,394,467 shares, compared to its average volume of 1,965,420. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -6.78 and a beta of 1.14. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $29.50 and a 200 day simple moving average of $29.68. uniQure has a 12-month low of $8.73 and a 12-month high of $51.72.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. As a group, analysts predict that uniQure will post -3.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of large investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new stake in shares of uniQure in the 2nd quarter valued at $15,254. IFP Advisors Inc grew its holdings in uniQure by 18.0% during the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 500 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in uniQure during the third quarter worth about $86,000. Activest Wealth Management purchased a new position in uniQure during the third quarter valued at approximately $121,000. Finally, Rangeley Capital LLC raised its position in uniQure by 52.9% during the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 4,500 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.